biomed devic servic
disrupt keep us sidelin
applaud honor role serv fight
opinion expect global pandem shed light util sequenc
applic infecti diseas beyond oncology-heavi focu said
invest perspect busi offer near-term resili like
see look play precis medicin mega-trend expect
see attract opportun buy road hold pt
revenu y/i match ilmn pre-announc beat
driven y/i growth sequenc consum vs
off-set y/i declin sequenc instrument rev declin
microarray servic rev sequenc servic revenu y/i beat
estim due higher y/i licens payment adj ep y/
came estim adj gm y/i beat
driven higher mix consum adj om beat due
lower expect project spend reduc labor-rel spend reduc travel
previous updat model
updat withdrawn guid offer qualit commentari expect
extrem challeng quarter revenu declin sequenti
geograph region america contribut largest declin absolut
dollar indic sequenc consum research purpos
current run level sequenc consum clinic use
current run level given tradit split
research/clin sequenc consum sale simpl math suggest
current consum volum run level run rate
indic research clinic run volum increas modestli
sequenti basi week begin april though earli call trend
clarifi withdrawn guidanc includ prior revenu ep target
addit comment relat instrument name novaseq pull
nextseq shipment popgen expect
time popul sequenc project big question mark confirm
shelter-in-plac requir led paus popul sequenc
popgen project sampl collect becom challeng saw number
popgen project delay larg due administr challeng get
variou constitu stakehold sign project prepar launch
wait updat timelin sever popgen projects- indic
uk biobank announc march paus sequenc three-
month us us initi immun us uk-bas
popul sequenc project materi disrupt lack visibl
governments/stakehold ous/emerg countri equip bounce-back
pace may see develop countri deal highli complex
requir care planning/design patient consent
may role play test immin
believ ngs-base test may valuabl reflex test posit pcr test
investig sampl diseas surveil mutat track
contact trace high throughput screen asymptomat patient help
inform decis return societi view three promis applic
see immin test revenu opportun
read through coverag highlight nipt specif exampl
resili ngs-base clinic test posit read indic
ngs-base oncolog test also hold well posit readthrough gh
price close busi may
hub precis medicin
domin global leader next gener
sequenc instrument consum
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object
view compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
model updat model assum major driven weak follow
sequenti acceler throughout back half lower rev
y/i lower revenu
y/i lower adj ep estim
launch expect earli januari announc launch
nextseq launch late nextseq expect launch
sequenc system integr edico genom acquir dragen
technolog expect improv time result higher throughput core
lab small medium research lab clinic facil expect
nextseq cannib novaseq custom base high end
nextseq output gigabas low end novaseq output
gigabas clear gap nextseq us list price
nextseq price respect ship
nextseq analyz hiseq convers custom expect modest
cannib novaseq convers among remain hiseq user expect
convert also announc develop new novaseqdx platform
expect launch avail ivd partner like roch
content develop ahead formal launch
array servic total services/oth rev y/i came
estim microarray consum y/i beat
estim microarray instrument revenu light microarray
servic rev declin y/i
releas data toolkit support research analysi
share genom data relat sever acut respiratori syndrom
coronaviru outbreak releas data toolkit
toolkit integr world-wide instal base sequenc
system design help global research commun public health
offici track path epidem understand transmiss rout determin
rate viral evolut understand viru chang way impact
biomed devic servic
detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact inform appear front page report
biomed devic servic
biomed devic servic
biomed devic servic
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research iii best author
analyst knowledg she/h receipt materi non-publ inform issuer
analyst employ outsid us regist research analyst finra analyst may associ
person canaccord genuiti llc therefor may subject finra rule nyse rule restrict
commun subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin may et
date time product may et
pt use multipl ep estim
pt gh use premium multipl revenu estim million discount back year
pt use multipl revenu estim discount back year discount rate
risk achiev target price valuat
believ key risk includ major new product launch novaseq instrument premium valuat
excess peer group risk associ demand pace novaseq placement hiseq unit
decommiss competit noise/tract though believ meaning competit risk well bay nih/
govern budgets/spend particularli foreign govern like japan genom research center regulatori
risk fda addit risk factor less concern includ typic medic technolog risk price instrument
consum risk associ move test clinic increas compani focu bioinformat
long-term also highlight spend scale helix
premium valuat gh trade premium multipl rel mani diagnost compani given gh best class liquid
biopsi portfolio huge believ valuat warrant bad news regulatori reimburs time product
launch shortfal financi could result lower move stock
risk obtain fda approv flagship test pan-canc label current
ldt gh take assay fda expedit access pathway via breakthrough devic design
eap design expect give prioriti review access senior fda offici doesnt guarante approv guardant
view fda approv signific mileston need facilit commerci adopt extend approv timelin would
pose risk project
risk obtain pan-canc medicar coverag today gh medicar coverag nsclc
guardant expect obtain pan-canc medicar coverag base expect fda approv guardant expect
nation coverag determin ncd test delay obtain pan-canc coverag would limit compani
opportun revenu
risk obtain fda approv guardantomni guardant recent launch guardant omni research use intend
take guardantomni fda obtain fda approv delay time rel expect could limit
compani opportun revenu
manag execut risk given technic natur develop liquid biopsi gh commerci success depend
manag abil launch new panel secur addit reimburs regulatori new label win
provid guidanc shortfal rel guid mark materi risk
biomed devic servic
risk launch commerci compani largest market opportun gh peg market
opportun high risk individu huge opportun primarili requir strong data gh
releas promis pilot data rel small sampl size guardant experi setback poor result
delay/cancel launch gh growth potenti would significantli reduc
competit guardant compet directli compani provid comprehens genom profil therapi select
foundat medicin roch think guardant like compet recurr monitoring/residu
diseas market among other guardant may compet screen diagnost compani includ exact
scienc colorect cancer screen possibl grail launch
reimburs risk end cover live think fda approv like drive
broader payor adopt larg health insur aet other current coverag decis guardant
fail increas reimburs coverag would limit opportun
risk relat intern expans guardant offer test countri outsid establish guardant
health amea softbank facilit expans asia middl east africa engag clinic trial work japan
lack compel data regulatori setback could delay expans plan ou addit guardant could struggl facilit
adopt emerg market due pricing/reimburs test
relianc sole supplier guardant reli heavili sole sequenc provid gh activ suppli agreement
decemb automat renew thereaft contract either parti option opt
agreement notic year advanc opt gh may struggl find replac sequenc meet
risk relat oper larg grow lab san francisco bay area home earthquak san francisco bay
area prone earthquak larg earthquak could interrupt lab oper compani lab headquart redwood
panorama asp compress erod margin gross margin drop sequenti
expect margin continu erod result reduct in-network price commerci payor come on-line
expand includ averag risk patient expect mitig revenu impact asp compress
drive busi profit account though busi may suffer increas test volum outpac
relianc lab partner move away lab partner priorit direct sale continu sell
number refer lab partner includ arup clarient sonic unclear durabl compani lab partnership
may particularli sinc lost lab partner past certain lab choos promot anoth nipt decid offer
nipt includ recent quest
fda oversight ldt test lab-develop test ivd fda take posit author
regul test medic devic fdc act gener chosen enforc author mandat
certain ltd seek fda clearanc howev fda look regul ldt use risk-bas approach begin
deem highest-risk devic follow lower risk devic believ panorama would treat moderate-risk
high-risk among highest-risk devic fda indic high-and moderate-risk ltd market
guidelin final remain market fda review submiss expect
requir remov product market regul fda ltd remain subject uncertainti
controversi
constel addit talk fda receiv clearanc constel us fda indic
constel platform may appropri review de novo classif allow market
distribut constel us convers on-going fda requir obtain regulatori
clearanc market constel softwar diagnost purpos abl secur fda clearanc
compli on-going fda regulatori requir would unabl commerci constel compani cloud-
competit compet directli compani offer nipt carrier screen test ob/gyn mfm
market labcorp roch counsyl mani compani larger abl
leverag economi scale win busi offer multipl test servic women health one requisit form
observ research doctor often switch test brand may make market share gain difficult
futur advers impact busi
strong competit oncolog uncertain time oncolog launch develop liquid biopsi test oncolog
manag size opportun billion initi sampl collect activ lung
ovarian cancer collect dozen collabor includ vanderbilt stanford columbia cancer research
uk other also initi collect effort breast cancer plan announc collabor later year
alon pursu blood-bas test oncolog market leader today substanti base
revenu data addit player includ foundat medicin roch grail person genom diagnost genom
counsyl trovagen pathway genom mdx name hand
ethic legal social concern relat genet inform could reduc demand genet test natera
test provid dna test servic like conduct use panorama expect conduct oncolog may
rais ethic legal social issu regard privaci appropri use result inform government author
biomed devic servic
could social purpos limit regul use genom inform genom test prohibit test genet
predisposit certain condit particularli known cure similarli concern may lead patient
refus use genet test even permiss ethic social concern may also complic abil protect patent
import medicaid nipt approxim birth unit state state medicaid program recipi
end recogn medicaid provid state state requir compani oper lab
state becom recogn medicaid provid typic medicaid rate price medicar commonli lowest
payor term dollar
distribut rate
global stock rate
total includ stock review
buy stock expect gener risk-adjust return next month
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
risk-adjust return refer expect return relat amount risk associ design invest
relev issuer
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
